Mathieu Spaas

[Mathieu Spaas @MathieuSpaas]

📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors https://t.co/Tdqxk72OGi

[Mathieu Spaas @MathieuSpaas]

Absolutely, some more insight into overall disease burden is provided in the online supplements 🔎

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

@MathieuSpaas @JAMAOnc Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit.
https://t.co/hAZBi2LawL
If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.

[Mathieu Spaas @MathieuSpaas]

@gv_lazcano @JAMAOnc Similar to PEMBRO-RT and @seanmmcbride we hypothesized that higher SBRT doses might abrogate a potential immune stimulatory effect, based on preclinical data by @CVanpouilleBox

[Mathieu Spaas @MathieuSpaas]

📣We just published final results of our CHEERS trial @JAMAOnc investigating the combination of subtotal subablative SBRT ☢️ with anti-PD-(L)1 monotherapy 💉 in pts with advanced solid tumors https://t.co/Tdqxk72OGi

[Mathieu Spaas @MathieuSpaas]

@piet_ost @NoraSundahl @RotteySylvie @Kruse_Vibeke @daandm @BrochezLieve @willekedanckae @Van_den_Begin @GestelDirk @EHulstaert @Sj0mpie

[Mathieu Spaas @MathieuSpaas]

✅Conclusion: while safe, adding subablative multisite SBRT to anti-PD-(L)1 monotherapy did not result in a clinically meaningful benefit
🙏 Thank you to pts, families, trial staff and investigators for participating in this @komop_tgkanker and @VarianMedSys sponsored trial!

[Mathieu Spaas @MathieuSpaas]

👥 >2/3 polyM+ pts and >1st line systemic Tx
😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness
☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes

[Mathieu Spaas @MathieuSpaas]

This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020
➡️ Randomized 1:1 between 💉anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions

[Piet Ost @piet_ost]

Words of wisdom on the NIVES trial: SBRT + nivo in mRCC. Our take on what is next and abandon the quest for the "abscopal" effect. @MathieuSpaas @NoraSundahl @_ShankarSiva @rweichselbaum

https://t.co/itqxlIUYc2

[Melvin LK CHUA | FRCR, PhD, FASCO @DrMLChua]

Really pleased to bring this to fruition. Collaboration between multiple partners to shed insights on combination immunotherapy and radiotherapy, so as to guide best combination therapies! ⁦#RTimmuno #checkpoint blockade #precisionRT ⁦@ASTRO_org⁩ https://t.co/PuSN6yJMEK

[The Lancet Oncology @TheLancetOncol]

Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation https://t.co/ONB6jmL3iw

[Mathieu Spaas @MathieuSpaas]

@ReneeBultijnck @piet_ost @AustProstate @hagsie @NoraSundahl @EliseDeBleser @AurelieBruycker Seconded!

[Robbe Van den Begin @Van_den_Begin]

Great news. Let's include as many as possible in the CHEERS trial when starting anti PD(L)-1. Maybe we can further improve the outcome! @JulesBordet #OncoAlert